Edwards Lifesciences Corporation $EW Shares Sold by Investment House LLC

Investment House LLC cut its position in Edwards Lifesciences Corporation (NYSE:EW) by 17.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 120,800 shares of the medical research company’s stock after selling 24,864 shares during the period. Investment House LLC’s holdings in Edwards Lifesciences were worth $10,298,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after acquiring an additional 977,933 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,968 shares of Edwards Lifesciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $82.07, for a total value of $818,073.76. Following the sale, the vice president owned 22,798 shares in the company, valued at $1,871,031.86. The trade was a 30.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of Edwards Lifesciences stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares in the company, valued at $3,278,948.54. This represents a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 106,684 shares of company stock worth $8,811,739 over the last quarter. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $82.13 on Wednesday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The company has a market cap of $47.29 billion, a price-to-earnings ratio of 43.69, a PEG ratio of 2.07 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The business’s 50 day moving average price is $81.48 and its 200 day moving average price is $82.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter last year, the business posted $0.64 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EW. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Wednesday, April 1st. BTIG Research lifted their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Evercore reiterated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.